Fundraising Fox

CuraSen Therapeutics, Inc.

San Carlos, US · Founded 2016 · Delaware corporation · 20 employees on LinkedIn · 3 known investors

Biotech

Founders & leadership

CuraSen Therapeutics, Inc. was founded in 2016 by Anthony P. Ford.

AP
Anthony P. FordFounder
BP
Benjamin PotterExecutive
HS
Henry SkinnerNamed on SEC filing
LR
Liam RatcliffeNamed on SEC filing

Board

RH
Ron HuntBoard director
LT
Loretta Tse, Ph.D.Board director
ST
Simon Tate, Ph.D.Board director
PE
Patrick EnrightBoard director
KS
Kathleen Sereda GlaubBoard director

Investors · 3

Alta PartnersJackson · $1M – $12M
New Leaf Venture PartnersreportedNew York

Also in the syndicate · 1

Alzheimer’s Drug Discovery Foundation (ADDF)

Reported raises · per SEC filings

Form D private placements

$68.6M disclosed across 4 of 5 rounds · 2018–2024

▶$5.8MraisedSep 2024 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Ron HuntDirector
  • Anthony P. FordExecutive Officer, Director
  • Benjamin PotterExecutive Officer
  • Loretta Tse, Ph.D.Director
  • Kathleen Sereda GlaubDirector
  • Simon Tate, Ph.D.Director
  • Patrick EnrightDirector
Offering amount
$45.7M
Amount sold
$5.8M
First sale
Aug 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$17.6MraisedOct 2023 · 11 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Anthony P. FordDirector, Executive Officer
  • Simon TateDirector
  • Patrick EnrightDirector
  • Loretta Tse, Ph.D.Director
  • Benjamin PotterExecutive Officer
  • Kathleen Sereda GlaubDirector
  • Ron HuntDirector
Offering amount
$20.8M
Amount sold
$17.6M
First sale
Nov 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$18MraisedNov 2021 · 10 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Patrick EnrightDirector
  • Benjamin PotterExecutive Officer
  • Anthony P FordDirector, Executive Officer
  • Ron HuntDirector
  • Loretta Tse, Ph.D.Director
  • Simon TateDirector
  • Kathleen Sereda GlaubDirector
Offering amount
$18M
Amount sold
$18M
First sale
Oct 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$27.2MraisedJan 2019 · 10 investors · Biotechnology
Rule 506(c)
Officers, directors & promoters on the filing
  • Henry SkinnerDirector
  • Patrick EnrightDirector
  • Liam RatcliffeDirector
  • Benjamin PotterExecutive Officer
  • Anthony P. FordExecutive Officer, Director
  • Kathleen Sereda GlaubDirector
Offering amount
$54.5M
Amount sold
$27.2M
Minimum investment
$1
First sale
Sep 2018
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06c
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

CuraSen Therapeutics Announces Strategic Investment from the Alzheimer’s Drug Discovery Foundation to Advance CST-3056, an Alpha-1A Adrenoceptor Agonist, for the Treatment of Alzheimer’s Disease | CuraSencurasen.com · Oct 2023CuraSen Therapeutics Announces $54.5 Million Series A Financing - Pappas Capitalpappas-capital.com · Oct 2018CuraSen Therapeutics Announces $54.5 Million Series A Financing with Industry Veterans at Helm to Develop Drugs Targeting Novel Mechanism for the Treatment of Neurodegenerative Diseases | CuraSencurasen.com · Oct 2018

Frequently asked questions

Who founded CuraSen Therapeutics, Inc.?
CuraSen Therapeutics, Inc. was founded by Anthony P. Ford in 2016.
Who are CuraSen Therapeutics, Inc.'s investors?
CuraSen Therapeutics, Inc.'s investors include Alta Partners, New Leaf Venture Partners.
How much funding has CuraSen Therapeutics, Inc. raised?
CuraSen Therapeutics, Inc. has disclosed $68.6M raised across 4 of its 5 known rounds.
Where is CuraSen Therapeutics, Inc. headquartered?
CuraSen Therapeutics, Inc. is headquartered in San Carlos, US.